



US 20140037646A1

(19) **United States**

(12) **Patent Application Publication**
Libert et al.

(10) **Pub. No.: US 2014/0037646 A1**
(43) **Pub. Date:** **Feb. 6, 2014**

(54) **MMP8 INACTIVATING ANTIGEN BINDING PROTEINS**

Publication Classification

(51) **Int. Cl.**
C07K 16/40 (2006.01)
(52) **U.S. Cl.**
CPC **C07K 16/40** (2013.01)
USPC **424/158.1**; 530/389.8; 536/23.53;
435/252.3; 435/69.6; 435/7.4; 435/254.11;
435/254.2; 435/338

(75) Inventors: **Claude Libert**, Oudenaarde (BE); **Eline Dejonckheere**, Ghent (BE)

(73) Assignees: **UNIVERSITEIT GENT**, Gent (BE);
VIB VZW, Gent (BE)

(21) Appl. No.: **13/883,444**

ABSTRACT

(22) PCT Filed: **Nov. 2, 2011**

(86) PCT No.: **PCT/EP11/69238**

§ 371 (c)(1),
(2), (4) Date: **Oct. 24, 2013**

(30) **Foreign Application Priority Data**

Nov. 4, 2010 (GB) 1018602.1

Described are MMP8 inactivating antigen binding proteins, such as antigen binding proteins comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions; further described is the use of such antigen binding proteins to treat inflammation, such as, but not limited to, systemic inflammatory response syndrome, sepsis, LPS induced inflammation, renal ischemia/reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, Lyme arthritis and osteoarthritis.